Editor Brian Harrod Provides Comprehensive up-to-date news coverage, with aggregated news from sources all over the world from the Roundup Newswires Network
Britain is on a collision course with the European Union over vaccine shortages after Brussels refused to accept that people in the UK have first claim on Oxford/AstraZeneca doses produced in local plants.
The EU’s health commissioner outright dismissed on Wednesday an argument made by Pascal Soriot, the Anglo-Swedish company’s chief executive, that he was contractually obliged to supply the UK first.
Yesterday Britain passed a grim milestone. A further 1,631 deaths from Covid-19 were recorded, taking the official tally above 100,000, though data from the Office for National Statistics suggests the total number will now be nearer 120,000. In a briefing, Boris Johnson has said his government did everything it could to minimise the loss of life, but these deaths were far from inevitable. While the number of UK deaths has entered the hundreds of thousands, New Zealand has recorded only 25 deaths from Covid-19 so far. Taiwan has recorded seven, Australia 909, Finland 655, Norway 550 and Singapore 29. These countries have largely returned to normal daily life.
In the first year of the pandemic, the UK faced three big challenges. Our national government had no long-term strategy for suppressing the virus beyond a continual cycle of lockdowns. Even now we still don’t know what the government’s plans for the next six months are. In the early days of the pandemic, the UK treated Covid-19 like a bad flu. The government halted testing, and the initial plan seemed to be allow the virus to run unchecked through the population (the “herd immunity” approach). Finally, ministers have pitted the economy against public health, instead of realising that the health of the economy depends upon a healthy population.
AstraZeneca’s chief executive has insisted the UK will come first for vaccines as he rejected calls to divert doses to the European Union following a breakdown in supply.
Amid a growing row, Pascal Soriot, the French head of the pharmaceutical giant, said the UK was benefiting from being early to sign a contract for 100m doses.
The Oxford/AstraZeneca vaccine may be authorised only for younger people in Europe, because there is insufficient data on how well it works in the over-65s, the head of the regulatory body has suggested.
The European Medicines Agency (EMA) is expected to authorise the AstraZeneca vaccine at the end of this week, a month after it was approved in the UK.
Analysis: technical problem at Belgium plant failed to produce enough vaccine but EU demanding fulfilment of contract
AstraZeneca warned the European commission on Friday that there would be a significant shortfall in the promised 100m vaccine doses this quarter, of up to 60%. It says this is due to a technical issue: not enough vaccine is being produced by the main plant making the supplies destined for Europe, which is in Belgium.
A row has broken out after German newspapers suggested the Oxford/AstraZeneca vaccine might have a lower efficacy among the over-65s. Below we take a look at the claims, and whether we should be concerned.
The EU “means business”, Ursula von der Leyen has said, as the bloc doubled down on plans for tighter monitoring of vaccine exports to countries outside of the union, such as the UK.
Speaking at the World Economic Forum, the president of the European commission said the EU had invested billions and “companies must now deliver” to the 27 member states.
A group of celebrities have released a video addressing vaccine misinformation in BAME communities.
The group, including actors Adil Ray and Meera Syal, as well as cricketeer Moeen Ali and presenter Konnie Huq, appealed to black, Asian and ethnic minority communities in the UK to help address hesitancy around the Covid-19 vaccine.
Coronavirus has disproportionately impacted minority ethnic communities, but these communities have also been subject to misleading information around the vaccine.
‘Unfortunately we are now fighting another pandemic: misinformation,’ Ray, who helped organise the video, explained. ‘We all must do what we can and come together to fight this deadly virus. We hope this video can help dispel some of the myths and offer some encouragement for everyone to take the vaccine’
Late February Pfizer vaccine rollout planned. Meanwhile, South Australian authorities warn residents as bushfires erupt in Adelaide Hills. Follow all the latest updates, live
A truck carrying toilet paper has burst into flames, causing traffic chaos on Melbourne’s Eastern Freeway.
It is still unclear what caused the fire, but firefighters are on the scene, attempting to bring the fire under control.
The truck exploding into flames on the Eastern Freeway, Melbourne near the Elgar Rd exit. I saw this while passing by and hope no one is hurt. The fire is now out but traffic is banked up on the city-bound lane. A terrible incident on a 40c day. #truckOnFireMelbourneFreewaypic.twitter.com/tj5MANXAQh
The Bureau of Meteorology has said the heatwave is over in Melbourne and is easing in South Australia, with rain and thunderstorms expected later this evening.
Dean Narramore, a senior meteorologist at the BoM, warned that the focus will shift to New South Wales tomorrow, with temperatures forecast to get near 40C in Western Sydney, with the city expecting to reach 35C.
But by tomorrow night the cool change will have moved across all of south-eastern Australia and temperatures will return to near seasonal averages for the rest of the week.
Experts have called for greater clarity about the monitoring in place to assess the 12-week dosing interval for Covid vaccines, as the UK’s vaccination programme ramps up.
According to government data released on Sunday, a total of 6,353,321 people in the UK have received at least one dose of a Covid vaccine. A further slew of vaccination centres are due to open on Monday to speed up delivery of the jabs.
A representative of the UK’s vaccine advisory committee has defended its decision to delay giving people a second dose, saying it will “save many lives”, as the health secretary, Matt Hancock, warned lifting restrictions was “a long, long way off”.
Prof Anthony Harnden, of the Joint Committee on Vaccination and Immunisation (JCVI), said the evidence was still in favour of delaying the dose, after a small Israeli study on people over the age of 60 suggested a first dose gave just 33% protection from coronavirus.
Exactly a year after his first story about coronavirus, our science editor received the Pfizer injection last week. Here he reflects on a remarkable scientific achievement
I marked a grim anniversary in an unexpected manner last week. On 18 January last year, I wrote my first story about a mysterious disease that had struck Wuhan, in China, and which was now spreading around the world. More than two million individuals have since died of Covid-19, almost 100,000 of them in the UK.
Remarkably, 12 months to the day that the Observer published my story, I was given my first dose of Covid-19 vaccine, allowing me to follow nearly six million other newly immunised UK residents who are set to gain protection against a disease that has brought the planet to a standstill. It was a rare, comforting experience after a year of unremitting sadness and gloom.
The gap between the first and second dose of the Pfizer/BioNTech coronavirus vaccine must be reduced to ensure the vaccine is effective, senior doctors have warned.
Currently patients wait about three months to get their second dose. Prof Chris Whitty, the chief medical officer for England, said this was a “public health decision” to get the first jab to more people across the country.
A quick glance at the government’s coronavirus dashboard might be fuel for optimism. But new data suggests the picture may not be so rosy.
According to the dashboard, the number of people testing positive for Covid is falling: 37,892 positive tests were reported on Thursday, compared with 62,322 on 6 January. Cases by specimen date show similar trends.
Pharmaceutical companies should do more to transfer vaccine technology to prevent the poorest countries falling behind in the distribution of Covid-19 vaccines, according to an expert.
The warning came from Dag-Inge Ulstein, the co-chair of the global council trying to speed up access to Covid vaccines for the world’s poor, known as the Act (Access to Covid-19 Tools) Accelerator. Ulstein, Norway’s international development minister, oversees the drive to ensure vaccines reach the poor – the Covax programme.
India’s Covid-19 vaccine drive has been hampered by turnout as low as 22% in some states, as fears over the safety of the vaccine and the spread of misinformation has fuelled widespread hesitancy.
On Saturday, India launched the world’s largest vaccination programme as it began the massive task of vaccinating its 1.3 billion citizens against coronavirus.
Israel’s coronavirus tsar has warned that a single dose of the Pfizer/BioNTech vaccine may be providing less protection than originally hoped, as the country reported a record 10,000 new Covid infections on Monday.
In remarks reported by Army Radio, Nachman Ash said a single dose appeared “less effective than we had thought”, and also lower than Pfizer had suggested.
Supply delays underline there was no legal or economic justification for central planning
A storm is raging over the EU’s failure to have ordered more of the approved Covid-19 vaccines ahead of time. Stéphane Bancel, the chief executive of the US pharmaceutical company Moderna, which gained approval for its vaccine shortly after Pfizer/BioNTech, claims that the EU has relied too much on “vaccines from its own laboratories”.
Did the European commission prioritise supporting its own pharmaceutical industry over protecting human lives? In fact, matters are not as simple as that. Contrary to what Bancel wants us to believe, the EU has actually ordered too little of its ownvaccine. After all, the vaccine that is being administered most widely across the west was developed by a German company, BioNTech, and thus comes from the EU (though it was tested and partly produced in partnership with Pfizer in the US and with Fosun Pharma in China).
The emergence of more infectious variants of Sars-CoV-2 has raised questions about just how long our vaccines will remain effective for. Although there is little evidence that the current vaccines won’t work against the new variants, as the virus continues to mutate scientists are preparing themselves for having to make changes to the vaccines in response. Speaking to Dr Katrina Pollock, science correspondent Linda Geddes asks how we can tweak the vaccines against new variants, and how likely it is we’ll end up in a game of cat and mouse with the virus